CLABSI in Hematology and Oncology: Progress Toward Zero
A thorough review of five years of CLABSI data reveals key gaps in clinical knowledge that must be addressed to further reduce infection rates.
Studies show that suboptimal medication adherence may be a barrier to increased survival rates among adolescents and young adults with cancer. Anthony Audino, MD, explores the utility of medication adherence apps to meet the unique needs of these patients.
Novel Adjuvant Therapy Resolves Steroid-Refractory Acute Graft-Versus-Host Disease in a Pediatric Transplant Recipient
Physicians have successfully treated steroid-refractory gastrointestinal acute graft-versus-host disease with the monoclonal antibody vedolizumab in a pediatric allogeneic hematopoietic cell transplant recipient.
Harnessing the power of the immune system to overcome cancer, improve outcomes of bone marrow transplants and fight viral infections in immunocompromised pediatric patients is at the heart of cell therapy research.
Targeting alternative RNA splicing in tumor cells could lead to cancer therapies.
A highly targeted form of proton therapy – known as “FLASH” – will be investigated in clinical trial participants with certain newly diagnosed, recurrent or advanced cancers as part of central Ohio’s first and only proton therapy center, a collaborative effort of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and Nationwide Children’s Hospital.
You Might Also Be Interested In
Sign Up for PediatricsOnline
Subscribe to PediatricsOnline, a digital newsletter personalized for the pediatric provider to deliver up-to-date resources, research announcements and more.
Hematology, Oncology & Blood and Marrow Transplant
Our hematology, oncology, and blood and marrow transplant teams treat patients with all forms of cancer and blood disorders. Our specialists participate in collaborative research across the country and around the world to bring innovative treatments to our patients.